Allergan Inks $30M Deal With Restasis Buyers In Antitrust Suit

By Nadia Dreid (October 13, 2021, 4:55 PM EDT) -- Allergan has struck a $30 million deal with buyers of dry-eye medication Restasis to end allegations that the pharmaceutical giant fought to keep a generic version of the medication off the shelves.

The end buyers told U.S. District Judge Nina Gershon on Friday that the deal had been reached "after nearly four years of hard-fought litigation" and asked her to preliminarily approve their $30 million plan to put the claims to bed.

The settlement will encompass all the end-payer actions in the multidistrict litigation, according to the filing. It comes a year and a half after Allergan reached a similar deal...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!